Uncategorized
Anti-VEGFs may be associated with small IOP decrease, but changes not clinically relevant
BALTIMORE — Researchers found no clinically relevant difference between bevacizumab, aflibercept and ranibizumab and changes in IOP over time, even though the IOP changes are considered significant, according to a “hot topic” designated study at the Association for Research in Vision and Ophthalmology annual meeting.A total of 23,282 patients with age-related macular degeneration, diabetic macular edema, or branch or central retina vein occlusion with retinal edema from the IRIS Registry were included.